Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 96

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 96
---
 of additional financing efforts; |

| • | rumors relating to us or our competitors; |

| • | sales of our Depositary Shares by us, our insiders or our other shareholders; |

| • | changes in the structure of healthcare payment systems; |

| • | market conditions in the pharmaceutical and biotechnology sectors, or general volatility in the market 
 due to other factors;                                                                                  |

| • | third party reimbursement policies; |

| • | Brexit and any resulting economic or currency volatility; |

| • | developments concerning current or future collaborations, strategic alliances, joint ventures or similar 
 relationships; and                                                                                       |

| • | reviews of long-term values of our assets, which could lead to impairment charges that could reduce our 
 earnings.                                                                                               |

These and other market and
industry factors may cause the market price and demand for our Depositary Shares to fluctuate substantially, regardless of our actual
operating performance, which may limit or prevent investors from selling their Depositary Shares at or above the price paid for the Depositary
Shares, and may otherwise negatively affect the liquidity of our Ordinary Shares and Depositary Shares. The realization of
any of the above risks or any of a broad range of other risks, including those described in these “Risk Factors,” could
have a dramatic and material adverse impact on the market price of our Depositary Shares.

The liquidity of our Depositary Shares may have an adverse effect on share price.

In October 2024, we changed
the ratio of our Ordinary Shares to Depositary Shares, which had the effect of a one-for-25 reverse split of Depositary Shares and reduced
the amount of Depositary Shares publicly traded. There is a risk that there may not be sufficient liquidity in the market to accommodate
significant increases in selling activity or the sale of a large block of our securities. Our Depositary Shares have historically had
limited trading volume, which may also result in volatility.

We may be subject to securities litigation, which is expensive and could divert management attention.

The market price of our Depositary
Shares may be volatile, and in the past, some companies that have experienced volatility in the market price of their stock have been
subject to securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable
judgment. We also may decide to settle lawsuits on unfavorable terms.

Any such negative outcome
could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending